Entrada Therapeutics announced the presentation of new clinical and preclinical data supporting its Duchenne muscular dystrophy (DMD) franchise at the 29th Annual Congress of the World Muscle Society on October 9, 2024. Additional positive safety data from the completed Phase 1 clinical trial for ENTR-601-44 showed no adverse findings or clinically relevant changes to renal toxicity biomarkers at the highest dose tested.
These results reinforce the safety profile of ENTR-601-44 and support the planned Q4 2024 global regulatory filings for a Phase 2 clinical trial. The company also presented preclinical data for the first time for ENTR-601-45, demonstrating compelling in vivo dystrophin production and functional improvement.
This preclinical data supports the planned Q4 2024 regulatory filings for a global direct-to-patient Phase 2 clinical trial for ENTR-601-45. Entrada also plans to submit regulatory applications in 2025 for ENTR-601-50 to initiate a global Phase 2 clinical trial, further expanding its DMD pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.